Drug intelligence / Profile preview

esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A bismuth-containing quadruple therapy regimen used for the eradication of *Helicobacter pylori* (*H. pylori*) infection. This combination includes esomeprazole (a proton pump inhibitor), amoxicillin and clarithromycin (antibiotics), and bismuth potassium citrate. The regimen is typically administered for 7-14 days and has been studied as a treatment for *H. pylori* infection.

Other names: bismuth-containing quadruple therapyTPB therapy

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate.

Explore the full profile